Loading...

IRON DISC MEDICINE INC US FDA Inspections 8-K Filing

DSC

RN

DISC MEDICINE INC

(IRON)

2026 8-K

Financial Results Report

Workforce Reduction

Financial Results Announced

FDA Update Call

FDA Response Received

Cash Position Update

Conference Call Summary

Financial Results Announced

Funding Announcement

Financial Update

FDA Voucher Received

Board Resignation

Financial Statements

Financial Statements

Financial Results

FDA Meeting Update

Operational Update

Conference Call

Stock Offering Agreement

Financial Results

Clinical Trial Update

Financial Results

Annual Meeting of Stockholders

Underwriting Agreement

Clinical Trial Updates

Financial Results Announcement

Product Launches

Financial Results Announcement

Appointment of CFO and COO

Phase 2 BEACON Study Data R...

Phase 1b/2 Study Results

Agreement with Jefferies LLC

Financial Results Announcement

ASH Annual Meeting and Expo...

Departure of CFO

Open Market Sale Agreement

Termination of Sales Agreement

Financial Results Announcement

Public Offering

Suspended Offering

Annual Meeting of Stockholders

Initial Data from Phase 2 T...

Earnings Reports

Resignation of Director

Financial Results and Corpo...

Securities Purchase Agreement

Sales Agreement with SVB Se...

Entry into a Material Defin...

External Links:

On February 13, 2026, Disc Medicine, Inc. announced they received a Complete Response Letter (CRL) from the FDA regarding their drug application for bitopertin, aimed at treating erythropoietic protoporphyria (EPP). This indicates that the FDA did not approve the application in its current state, marking a significant setback for the company.

AI Assistant

DISC MEDICINE INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.